PURPOSE: We conducted a systematic review and meta-analysis to measure the extent to which race is associated with delayed initiation or receipt of inadequate chemotherapy among women with early-stage breast cancer. METHODS: We performed a systematic search of all articles published from January 1987 until June 2017 within four databases: PubMed/Medline, EMBASE, CINAHL, and Cochrane CENTRAL. Eligible studies were US-based and examined the influence of race on chemotherapy delays, cessation, or dose reductions among women with stage I, II, or III breast cancer. Data were pooled using a random effects model. RESULTS: A total of twelve studies were included in the quantitative analysis. Blacks were significantly more likely than whites to have delays to initiation of adjuvant therapy of 90 days or more (OR 1.41, 95% CI 1.06-1.87; X² = 31.05, p < 0.00001; I² = 90%). There was no significant association between race and chemotherapy dosing. Due to overlap between studies assessing the relationship between race and completion of chemotherapy, we conducted two separate analyses. Black patients were significantly more likely to discontinue chemotherapy, however, this was no longer statistically significant when larger numbers of patients with more advanced (stage III) breast cancer were included. CONCLUSIONS: These results suggest that black breast cancer patients experience clinically relevant delays in the initiation of adjuvant chemotherapy more often than white patients, which may in part explain the increased mortality observed among black patients.
PURPOSE: We conducted a systematic review and meta-analysis to measure the extent to which race is associated with delayed initiation or receipt of inadequate chemotherapy among women with early-stage breast cancer. METHODS: We performed a systematic search of all articles published from January 1987 until June 2017 within four databases: PubMed/Medline, EMBASE, CINAHL, and Cochrane CENTRAL. Eligible studies were US-based and examined the influence of race on chemotherapy delays, cessation, or dose reductions among women with stage I, II, or III breast cancer. Data were pooled using a random effects model. RESULTS: A total of twelve studies were included in the quantitative analysis. Blacks were significantly more likely than whites to have delays to initiation of adjuvant therapy of 90 days or more (OR 1.41, 95% CI 1.06-1.87; X² = 31.05, p < 0.00001; I² = 90%). There was no significant association between race and chemotherapy dosing. Due to overlap between studies assessing the relationship between race and completion of chemotherapy, we conducted two separate analyses. Black patients were significantly more likely to discontinue chemotherapy, however, this was no longer statistically significant when larger numbers of patients with more advanced (stage III) breast cancer were included. CONCLUSIONS: These results suggest that black breast cancerpatients experience clinically relevant delays in the initiation of adjuvant chemotherapy more often than white patients, which may in part explain the increased mortality observed among black patients.
Authors: D R Budman; D A Berry; C T Cirrincione; I C Henderson; W C Wood; R B Weiss; C R Ferree; H B Muss; M R Green; L Norton; E Frei Journal: J Natl Cancer Inst Date: 1998-08-19 Impact factor: 13.506
Authors: John M McLaughlin; Roger T Anderson; Amy K Ferketich; Eric E Seiber; Rajesh Balkrishnan; Electra D Paskett Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Dawn Hershman; Mitchell Weinberg; Zachary Rosner; Karenza Alexis; Amy Tiersten; Victor R Grann; Andrea Troxel; Alfred I Neugut Journal: J Natl Cancer Inst Date: 2003-10-15 Impact factor: 13.506
Authors: Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Debora de Melo Gagliato; Ana M Gonzalez-Angulo; Xiudong Lei; Richard L Theriault; Sharon H Giordano; Vicente Valero; Gabriel N Hortobagyi; Mariana Chavez-Macgregor Journal: J Clin Oncol Date: 2014-01-27 Impact factor: 44.544
Authors: K A Nyrop; E M Damone; A M Deal; S B Wheeler; M Charlot; B B Reeve; E Basch; S S Shachar; L A Carey; K E Reeder-Hayes; E C Dees; T A Jolly; G G Kimmick; M S Karuturi; R E Reinbolt; J C Speca; W A Wood; H B Muss Journal: Breast Cancer Res Treat Date: 2021-11-05 Impact factor: 4.872
Authors: Marc A Emerson; Yvonne M Golightly; Allison E Aiello; Katherine E Reeder-Hayes; Xianming Tan; Ugwuji Maduekwe; Marian Johnson-Thompson; Andrew F Olshan; Melissa A Troester Journal: Cancer Date: 2020-09-21 Impact factor: 6.860
Authors: Megan C Edmonds; Arnethea L Sutton; Jun He; Robert A Perera; Vanessa B Sheppard Journal: J Natl Med Assoc Date: 2020-03-18 Impact factor: 1.798
Authors: Xin Hu; Puneet K Chehal; Cameron Kaplan; Rebecca A Krukowski; Roy H Lan; Edward Stepanski; Lee Schwartzberg; Gregory Vidal; Ilana Graetz Journal: JAMA Netw Open Date: 2021-06-01